How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?

被引：6

作者：

Tsimihodimos, Vasilios ^{[1
]}

Florentin, Matilda ^{[1
]}

Elisaf, Moses S. ^{[1
]}

机构：

[1] Univ Ioannina, Sch Med, Dept Internal Med, GR-45110 Ioannina, Greece

来源：

CURRENT PHARMACEUTICAL DESIGN | 2013年 / 19卷 / 21期

关键词：

Aldosterone; angiotensin; dyslipidemia; fibrates; hypertension; new-onset diabetes; prediabetes; statins; IMPAIRED FASTING GLUCOSE; CORONARY-HEART-DISEASE; DEPENDENT DIABETES-MELLITUS; ISOLATED SYSTOLIC HYPERTENSION; CARDIOVASCULAR END-POINTS; BETA-CELL DYSFUNCTION; LOW HDL CHOLESTEROL; INSULIN-RESISTANCE; RISK-FACTORS; ANGIOTENSIN-II;

D O I：

10.2174/13816128113199990304

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Type 2 diabetes mellitus (T2DM) is a serious health problem with epidemic proportions and associated with high cardiovascular morbidity and mortality. Thus, the prevention or at least delaying the onset of T2DM is imperative. Subjects with impaired glucose metabolism (prediabetes) are highly likely to develop overt T2DM. Treatment of accompanied cardiovascular risk factors, such as hypertension and dyslipidemia, in these patients is frequently complicated as it can impair the already altered glucose homeostasis. This review discusses the pathophysiology of lipid disorders and hypertension in prediabetes along with the effects of lipid modifying and antihypertensive drugs in glucose/insulin metabolism. A critical overview and suggestions of different treatment options for prediabetic patients with dyslipidemia and/or hypertension are also presented.

引用

页码：3773 / 3787

页数：15

共 50 条

[21] How long should we treat?
C. Roux
K. Briot
[J]. Osteoporosis International, 2014, 25 : 1659 - 1666
[22] How should we best treat patients with bloodstream infections?
Eduardo Lopez-Cortes, Luis
de Cueto, Marina
Rodriguez-Bano, Jesus
[J]. FUTURE MICROBIOLOGY, 2017, 12 (11) : 927 - 930
[23] HOW SHOULD WE TREAT ANIMALS
CHALLINOR, D
[J]. NEW SCIENTIST, 1983, 98 (1354) : 155 - 156
[24] HOW LONG SHOULD WE TREAT?
Roux, C.
[J]. OSTEOPOROSIS INTERNATIONAL, 2012, 23 : 658 - 658
[25] HOW SHOULD WE TREAT ENVIRONMENT
HARE, FK
[J]. SCIENCE, 1970, 167 (3917) : 352 - &
[26] HOW LONG SHOULD WE TREAT?
Roux, Christian
[J]. OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S53 - S53
[27] How We Treat Dyslipidemia in Prolonged Nephrotic Syndrome
Ponticelli, Claudio
Arnaboldi, Lorenzo
Moroni, Gabriella
Fornoni, Alessia
[J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 19 (10): : 1327 - 1329
[28] Treating prediabetes: why and how should we do it?
Braga, Tassia
Kraemer-Aguiar, Luiz G.
Docherty, Neil G.
Le Roux, Carel W.
[J]. MINERVA MEDICA, 2019, 110 (01) : 52 - 61
[29] How should we treat tophaceous gout in patients with allopurinol hypersensitivity?
Grahame, R
Simmonds, HA
McBride, MB
Marsh, FP
[J]. PURINE AND PYRIMIDINE METABOLISM IN MAN IX, 1998, 431 : 19 - 23
[30] How should we treat patients with low serum thyrotropin concentrations?
Mitchell, Anna L.
Pearce, Simon H. S.
[J]. CLINICAL ENDOCRINOLOGY, 2010, 72 (03) : 292 - 296

← 1 2 3 4 5 →